Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Medexus Pharmaceuticals Inc ( (TSE:MDP) ).
Medexus Pharmaceuticals has successfully completed agreements with Ontario’s Ministry of Health and Ontario Health for public reimbursement of Trecondyv in Ontario, Canada. This milestone follows the completion of pCPA negotiations and signifies progress in making Trecondyv accessible across Canada. The company is working with other government organizations to further expand public reimbursement, enhancing its market presence and providing critical treatment options for patients with acute myeloid leukemia and myelodysplastic syndromes.
More about Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc is a company operating in the pharmaceutical industry, focusing on the production and distribution of specialty drugs. Its primary products include Trecondyv (treosulfan for injection), used in stem cell transplantation regimens, and GRAFAPEX (treosulfan) for Injection, recently approved by the FDA for the U.S. market.
YTD Price Performance: 11.59%
Average Trading Volume: 92,878
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: C$94.91M
For a thorough assessment of MDP stock, go to TipRanks’ Stock Analysis page.
